| Cash flow (USD) | FY 2025 ended Dec 31, 2025 | FY 2024 ended Dec 31, 2024 | FY 2023 ended Dec 31, 2023 | FY 2022 ended Dec 31, 2022 | FY 2021 ended Dec 31, 2021 | FY 2020 ended Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Net income | 8.51B | 480.00M | 5.67B | 4.59B | 6.22B | 123.00M |
| Depreciation and amortization | 370.00M | 381.00M | 354.00M | 323.00M | 329.00M | 288.00M |
| Stock-based compensation | 894.00M | 835.00M | 766.00M | 637.00M | 635.00M | 643.00M |
| Cash from operations | 10.02B | 10.83B | 8.01B | 9.07B | 11.38B | 8.17B |
| Capital expenditure | -563.00M | -523.00M | -585.00M | -728.00M | -579.00M | -650.00M |
| Free cash flow | 9.46B | 10.30B | 7.42B | 8.34B | 10.80B | 7.52B |
| Acquisitions | -1.07B | -4.84B | -1.15B | -1.80B | -1.58B | -25.92B |
| Cash from investing | -4.79B | -3.45B | -2.27B | -2.47B | -3.13B | -14.62B |
| Dividends paid | -4.00B | -3.92B | -3.81B | -3.71B | -3.60B | -3.45B |
| Share buybacks | -1.92B | -1.15B | -1.00B | -1.40B | -546.00M | -1.58B |
| Net debt issued | -1.79B | -1.97B | -2.25B | -1.50B | -4.75B | -2.50B |
| Cash from financing | -7.75B | -3.43B | -5.13B | -6.47B | -8.88B | 770.00M |
| Net change in cash | -2.43B | 3.91B | 673.00M | 74.00M | -659.00M | -5.63B |
From Gilead Sciences's 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read cash flow or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.